AbSci, a biotherapeutic discovery and manufacturing technologies company, has entered a collaboration with Sanofi. AbSci will apply its E.coli manufacturing platform, SoluPro, and its optimization assay system, to two of Sanofi’s biotherapeutic molecules. AbSci’s technology platform is designed with the ability to rapidly achieve optimized, scalable, high-quality, high-titer production of any class of biotherapeutic molecule, including traditionally difficult to manufacture molecules and next-generation scaffolds. The collaboration will take place at AbSci and will be funded by Sanofi.

“It is exciting to partner with a renowned company like Sanofi,” said Sean McClain, chief executive officer of AbSci. “This collaboration illustrates the need for new expression technologies that are capable of producing these next-generation antibody and protein scaffolds. We’ve shown SoluPro can uniquely deliver on this industry need.”